IMMUNITYBIO, INC. Current Liabilities
IMMUNITYBIO, INC. (IBRX) had Current Liabilities of $76.73 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-04
- 2026-06-30: Liabilities, Current $76.73M.
- 2026-03-31: Liabilities, Current $67.95M.
- 2025-12-31: Liabilities, Current $61.75M.
- 2025-09-30: Liabilities, Current $57.13M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $76.73M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $67.95M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $61.75M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $57.13M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $50.64M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $49.20M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $54.94M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $60.96M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $62.11M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $53.76M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $58.28M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $90.32M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $613.48M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $564.95M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $500.86M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $70.84M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $376.05M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $381.01M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $369.00M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $65.41M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $74.43M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $79.86M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $68.13M 10-K · filed 2022-03-01 | $24.65M 10-K · filed 2021-03-04 |
| 2020-09-30 | $20.66M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $17.05M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $14.25M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $48.49M 8-K/A · filed 2021-04-22 | $11.56M 10-K · filed 2020-03-25 |
| 2019-09-30 | $12.52M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $12.43M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $27.70M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $27.26M 10-K · filed 2020-03-25 | |
| 2018-09-30 | $30.40M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $20.19M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $19.40M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $20.87M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $28.67M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $36.88M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $14.20M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $12.55M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $10.23M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $10.04M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $7.86M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $6.15M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $6.68M 10-Q · filed 2015-11-12 | |
| 2014-12-31 | $1.88M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |